Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 10/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.41 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | DDX3X | O00571 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25787836 | 0.92 | ABCG2 (0.41) | ABCG2ABCB1TAS2R14MAPTSMN1; SMN2 | |
| SCHEMBL20552459 | 0.89 | ABCG2 (0.47) | ABCG2ABCB1MAPTSMN1; SMN2DDX3X | |
| SCHEMBL20551929 | 0.87 | USP2 (0.48) | ABCG2ABCB1TAS2R14MAPTSMN1; SMN2 | |
| SCHEMBL20552901 | 0.87 | ABCG2 (0.41) | ABCG2ABCB1TAS2R14MAPTSMN1; SMN2 | |
| SCHEMBL21749269 | 0.86 | ABCG2 (0.46) | ABCG2ABCB1TAS2R14MAPTSMN1; SMN2 | |
| SCHEMBL20552643 | 0.85 | ABCG2 (0.47) | ABCG2ABCB1TAS2R14MAPTSMN1; SMN2 | |
| SCHEMBL20552265 | 0.85 | ABCG2 (0.45) | ABCG2ABCB1TAS2R14MAPTSMN1; SMN2 | |
| SCHEMBL20552624 | 0.85 | ABCG2 (0.47) | ABCG2ABCB1TAS2R14MAPTSMN1; SMN2 | |
| SCHEMBL28396773 | 0.85 | ABCG2 (0.42) | ABCG2ABCB1TAS2R14MAPTSMN1; SMN2 | |
| SCHEMBL21749260 | 0.85 | ABCG2 (0.42) | ABCG2ABCB1MAPTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-11186554-B2 | Non-fused tricyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11186554-B2 | Non-fused tricyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20200062721-A1 | NON-FUSED TRICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2020-02-27 | — | — | US | disclosed |
| US-20200062721-A1 | NON-FUSED TRICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062721-A1 | NON-FUSED TRICYCLIC COMPOUNDS | YAP1, MYC, TEAD2 | ABCG2 3004/4885ABCB1 1774/4885TAS2R14 4740/4885 |
| US-11186554-B2 | Non-fused tricyclic compounds | YAP1, MYC, TEAD2 | ABCG2 3004/4885ABCB1 1774/4885TAS2R14 4740/4885 |
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | ABCG2 2217/4885ABCB1 1588/4885TAS2R14 3753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.